Series D · Healthtech

Science Corporation raises $400m Series D for neural interfaces

The financing supports the PRIMA vision-restoration system and development of biohybrid neural interfaces.

Science Corporation announced a $400 million Series D on November 17. Participants included Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.

The company develops neural interfaces, including PRIMA, a retinal implant system designed to restore useful vision to people with severe sight loss. The funding supports commercialization of PRIMA and research on biohybrid interfaces that combine living cells with electronics.

PRIMA is commercially available in Europe. Science is pursuing a US humanitarian device exemption from the FDA.

Use of funds

PRIMA availability in Europe

US regulatory preparation

Research manufacturing and operations

Biohybrid neural interfaces

Funding history

Series D · This round$400M
Series C$230M

Sources

  1. Science Corporation Series D financing announcementscience.xyz · Nov 17, 2026
  2. Science Corporation’s brain tech is worth $3.5 billion after new fundingtechcrunch.com · Nov 17, 2026